Trial Profile
A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Oct 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Bempegaldesleukin (Primary) ; Enzalutamide (Primary) ; Talazoparib (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAVELIN IL-2 Medley
- Sponsors Pfizer
- 18 Dec 2020 This trial has been completed in Poland according to European Clinical Trials Database record.
- 30 Nov 2020 Status changed from completed to discontinued.
- 26 Nov 2020 This trial has been discontinued in Italy according to European Clinical Trials Database record.